Drug Trial Radar · NCT06039579
Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults
Last checked: Nov 20, 2026Latest source record: Sep 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
44
Actual
Start
Oct 25, 2023
Primary completion
Jun 24, 2024
Study completion Jun 24, 2024
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- First posted
- Sep 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of the study is to evaluate the antiviral activity of orally administered VH4004280 and VH4011499 monotherapy over 10 days in human immunodeficiency virus (HIV-1) infected Treatment-Naïve (TN) participants.
Conditions
- HIV Infections
Interventions
VH4004280Drug
VH4004280 was administered as tablets orally at Day 1.
VH4011499Drug
VH4011499 was administered as tablets orally at Day 1 and Day 6.
VH4004280 Matching PlaceboDrug
VH4004280 Matching Placebo was administered as tablets orally at Day 1.
VH4011499 Matching PlaceboDrug
VH4011499 Matching Placebo was administered as tablets orally at Day 1 and Day 6.
Antiretroviral therapyDrug
Antiretroviral therapy was administered as available and as per investigator's recommendation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Monotherapy, VH4004280: Maximum Change From Baseline (Day 1) in Plasma HIV-1 Ribonucleic Acid (RNA) log10Time frame: From Baseline (Day 1) and up to Day 11
- Monotherapy, VH4011499: Maximum Change From Baseline (Day 1) in Plasma HIV-1 RNA log10Time frame: From Baseline (Day 1) and up to Day 11
Locations
20 sites in 9 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Bakersfield, California
GSK Investigational Site
DeLand, Florida
GSK Investigational Site
Newark, New Jersey
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Ciudad Autonoma de Bueno, Argentina
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Marseille, France
GSK Investigational Site
Nantes, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Cologne, Germany
GSK Investigational Site
Milan, Italy
GSK Investigational Site
Guadalajara, Mexico
GSK Investigational Site
Mexico City, Mexico
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.